RNase HII-assisted amplification (RHAM) for rapid point-of-care monkeypox detection

This study demonstrates that the Pluslife Biotech RHAM assay is a rapid, extraction-free, point-of-care molecular test capable of detecting all monkeypox virus clades with high sensitivity and specificity across diverse clinical specimens, offering a practical solution for outbreak control in resource-limited settings.

The Gist

The "Smart Flashlight" for Monkeypox: A New Way to Find the Virus Fast

Imagine Monkeypox (Mpox) is a sneaky intruder hiding in a dark house. Traditionally, to find this intruder, you had to send a sample to a high-tech, expensive laboratory. There, a team of experts in white coats would use a giant, complex machine (like a sophisticated DNA scanner) to hunt for the virus. This process takes hours, costs a lot of money, and requires the house to have perfect electricity and climate control. If you are in a remote village or a place without a big lab, you might have to wait days for an answer, giving the intruder time to spread.

This paper introduces a new tool called Pluslife RHAM. Think of it as a smart, portable flashlight that can find the intruder right where you are, in under 30 minutes, without needing a lab.

Here is a breakdown of how it works and why it matters, using simple analogies:

1. The Problem: The "Gold Standard" is Heavy

The current "Gold Standard" for finding Monkeypox is a test called Real-time PCR.

• The Analogy: Imagine trying to find a specific needle in a haystack, but you have to first build a factory to process the hay, then ship the hay to a distant city, and wait for a master craftsman to sort it. It's accurate, but it's slow and requires a lot of infrastructure.
• The Issue: Many places where Monkeypox is spreading don't have these factories or master craftsmen.

2. The Solution: The "Magic Sponge" (RHAM Technology)

The researchers tested a new device by a company called Pluslife. It uses a technology called RHAM (RNase HII-assisted amplification).

• The Analogy: Instead of building a factory, imagine you have a magic sponge. You just drop the sponge (the sample) into a special bucket (the test card). The sponge instantly soaks up the virus and makes it glow bright red if it's there.
• No Extraction Needed: Usually, you have to wash the virus out of the sample first (like squeezing a wet sponge). This new test skips that step. You can just drop the swab or urine directly into the mix. It's "extraction-free," meaning it's much faster and easier.

3. How Accurate is the Flashlight?

The scientists tested this "smart flashlight" against the heavy-duty lab machines using 206 real patient samples (like skin swabs, throat swabs, and even urine).

• The Results:
  • Specificity (No False Alarms): If the flashlight said "No virus," it was 100% correct. It didn't get confused by other viruses like chickenpox or herpes. It only sees Monkeypox.
  • Sensitivity (Finding the Intruder): If the virus was present, the flashlight found it 94% of the time.
  • The "High Load" Rule: When the virus was strong (lots of it), the flashlight found it 100% of the time.
  • The Missed Cases: The few times it missed the virus, the virus was very weak (like a whisper in a noisy room) and the sample had been frozen for a long time.

4. Speed: The "Time-to-Result" Trick

One of the coolest features is how the test tells you how much virus is there without counting it.

• The Analogy: Think of the test like a race car. If the virus is strong (a Ferrari), the car zooms to the finish line in 10 minutes. If the virus is weak (a bicycle), it takes 25 minutes.
• Why it matters: The faster the result, the sicker the patient likely is. This helps doctors decide who needs immediate isolation or treatment right away.

5. Why This Changes Everything

The paper argues that this tool is a game-changer for the world, especially for places that are poor or far away.

• Cost: The big lab machines cost thousands of dollars. This new device costs about $300 to buy, and each test is about $11.
• Portability: It fits in a backpack. You don't need a lab, a generator, or a PhD to use it.
• Versatility: It works on skin sores, throat swabs, rectal swabs, and even urine.

The Bottom Line

This paper says we have a new portable, fast, and cheap flashlight that can find Monkeypox almost as well as the giant lab machines. It doesn't need a lab, it works in 30 minutes, and it gives doctors the power to stop outbreaks before they spread, even in the most remote corners of the world. It's like moving from waiting for a mail-order package to getting a text message instantly.

Technical Summary

1. Problem Statement

• Global Threat: Monkeypox (Mpox), caused by the Monkeypox virus (MPXV), remains a significant public health threat with outbreaks occurring beyond traditional endemic regions in Africa (specifically Clade I and II).
• Diagnostic Limitations:
  • Gold Standard Constraints: Real-time PCR is the current gold standard but requires specialized laboratory infrastructure, trained personnel, and nucleic acid extraction, making it inaccessible in resource-limited settings.
  • Rapid Test Shortcomings: Antigen-based lateral flow assays (LFAs) are rapid but lack the sensitivity required by WHO criteria. Existing molecular Point-of-Care (POC) tests (e.g., Cepheid Xpert) have shown suboptimal sensitivity (74–79%) in independent evaluations and often fail to meet WHO target product profiles for endemic settings.
• Need: There is a critical need for a rapid, sensitive, extraction-free molecular diagnostic tool that can be deployed in decentralized, low-resource environments to facilitate timely outbreak control.

2. Methodology

The study evaluated the Pluslife RHAM (RNase HII-assisted amplification) test, a novel isothermal amplification technology developed by Pluslife Biotech.

• Technology: RHAM combines Loop-mediated Isothermal Amplification (LAMP) with an RNase HII-dependent reporter system. It operates at a constant temperature (isothermal), eliminating the need for thermal cyclers.
• Workflow: The test is extraction-free. Samples (swabs or transport media) are mixed directly with a nucleic acid releasing agent and added to a lyophilized reaction card. Results are read via a portable "Mini Dock" device in under 30 minutes.
• Study Design & Samples:
  • Location: German Consultant Laboratory for Poxviruses (Robert Koch Institute).
  • Specimens: 206 clinical samples (lesion swabs, crusts, oropharyngeal/rectal swabs, urine, semen, wound exudate) collected between 2022–2025.
  • Reference Standard: Diagnostic real-time PCR (accredited DIN ISO 15189) and digital PCR (dPCR) for viral load quantification.
  • Analytical Evaluation:
    • Specificity: Tested against a panel of Orthopoxviruses (Cowpox, Vaccinia, etc.), non-OPXV poxviruses (Orf, Molluscum), and other relevant pathogens (HSV, VZV).
    • Sensitivity: Serial dilutions of MPXV culture supernatants for all four clades (Ia, Ib, IIa, IIb) were tested to determine Limits of Detection (LoD).
  • Statistical Analysis: Sensitivity and specificity were calculated against real-time PCR using the Clopper-Pearson method. Correlation between viral load (Ct values) and time-to-result was assessed via Spearman's rank correlation.

3. Key Contributions

• Pan-Clade Detection: The assay demonstrated reactivity against all four MPXV clades (Ia, Ib, IIa, IIb), addressing the genetic diversity of current and emerging outbreaks.
• Extraction-Free POC Workflow: The study validated a workflow that eliminates the need for nucleic acid extraction, significantly reducing processing time, biosafety requirements, and equipment needs.
• Comprehensive Clinical Validation: Unlike many POC studies limited to lesion swabs, this evaluation included a wide variety of specimen types (urine, semen, wound exudate) and compared performance against a rigorous reference standard in a routine diagnostic setting.
• Cost and Infrastructure Analysis: The paper provides a comparative economic analysis, highlighting the lower capital and per-test costs of the RHAM platform compared to established systems like GeneXpert.

4. Key Results

• Analytical Specificity: The test showed 100% specificity, yielding negative results for all non-MPXV pathogens tested, including other Orthopoxviruses and Herpesviruses.
• Analytical Sensitivity (LoD):
  • Clade Ia & Ib: Detected at low viral loads (approx. 200 and 8 copies/PCR reaction, respectively).
  • Clade IIa & IIb: Detected at 2,765 and 292 copies/PCR reaction, respectively.
  • Note: Sensitivity varied slightly by clade, with Clade IIb showing the highest sensitivity in culture supernatants.
• Diagnostic Performance (Clinical Samples):
  • Sensitivity: 94.2% (95% CI: 85.8–98.4%).
  • Specificity: 100% (95% CI: 97.3–100%).
  • High Viral Load Performance: Samples with Ct < 30 (high viral load) showed **100% sensitivity**. The four false negatives were all archived samples with Ct > 30.
• Specimen Compatibility:
  • High Performance: Lesion swabs, crusts, oropharyngeal swabs, and rectal swabs showed consistent detection.
  • Variable Performance: Wound exudate and urine showed good detection (4/5 positive). Semen showed lower performance (3/5 positive), likely due to PCR inhibition, suggesting it is better suited as a supplementary rather than primary sample type.
• Time-to-Result Correlation: A statistically significant positive correlation was found between viral load and time-to-result (Spearman's r = 0.7613, p < 0.0001). Higher viral loads resulted in faster detection, allowing for semi-quantitative assessment.

5. Significance and Conclusion

• Operational Impact: The Pluslife RHAM test offers a practical solution for resource-limited settings. It requires minimal infrastructure (no cold chain for reagents, no complex extraction), has a low capital cost ($298 for the device vs. ~$17,000 for GeneXpert), and a lower per-test cost ($11 vs. ~$20).
• Outbreak Control: By providing results in <30 minutes with high accuracy, the test enables rapid isolation, contact tracing, and clinical decision-making, which are critical for containing MPXV transmission.
• Future Outlook: While the test performs exceptionally well on primary lesion samples, further field evaluations in endemic regions are recommended to assess operational feasibility and user acceptability in real-world constraints. The technology represents a significant step forward in democratizing molecular diagnostics for emerging viral threats.